HONOLULU--(BUSINESS WIRE)--The Medicines Company (NASDAQ: MDCO) announced today that its investigational agent, CleviprexTM (clevidipine butyrate injectable emulsion), rapidly achieved and maintained blood pressure control in patients with renal dysfunction (RD) and patients with acute heart failure (AHF), according to two new analyses from the Phase III trial VELOCITY1 presented at the annual meeting of the Society of Clinical Care Medicine (SCCM).
